Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — Q4 FY2022 Earnings Presentation
14 slides from Angiodynamics's earnings presentation, Jul 12, 2022
Slide 1: Fourth Quarter 2022 Earnings Presentation
ANGIODYNAMICS Fourth Quarter 2022 Earnings Presentation July 12, 2022 1
Slide 2: Forward-Looking Statement
2 Forward-Looking Statement Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations,
Slide 3: Corporate Developments – Q4 and Full-Year Highlights
Corporate Developments – Q4 and Full-Year Highlights Continued focused investment in our 3 key Med Tech platforms: Auryon, Thrombectomy & NanoKnife Macroeconomic headwinds persist Gross margin impacted by supply chain disruptions, labor shortages and inflation Manufacturing capacity enhancement drov
Slide 4: FY23 Guidance
FY23 Guidance 4 FY23 Guidance Q4 FY2022 Revenue $342 - $348 million Gross Margin Med Tech Med Device 52.5% - 54.5% 65% - 68% 45% - 48% Adjusted EPS $0.01 - $0.06
Slide 5: Fourth Quarter and Full-Year Highlights
Fourth Quarter and Full-Year Highlights Q4 FY2022 Q4 FY2021 Change FY2022 FY2021 Change Revenue $86,998 $76,842 13.2% $316,219 $291,010 8.7% Gross Margin 53.4% 55.1% (170 bps) 52.4% 53.9% (150 bps) Net Loss ($6,266) ($19,468) $13,202 ($26,547) ($31,548) $5,001 GAAP EPS ($0.16) ($0.51) $0.35 ($0.68)
Slide 6: Fourth Quarter and Full-Year Highlights
Fourth Quarter and Full-Year Highlights 6 Med Device Med Tech $10.5 $17.6 $59.7 40.0% growth 6.1% growth Q4 Revenue Growth Q4 FY21 Q4 FY22 Full-Year Revenue Contribution Med Device Med Tech FY21 FY22 41.2% growth 0.9% growth Q4 Revenue Contribution Full-Year Revenue Growth 19.6 54.4 Q4 FY21
Slide 7: Sales Growth Over Prior Periods
Sales Growth Over Prior Periods Endovascular Therapies Q4 FY2022 FY2022 Auryon 110% 162% Mechanical Thrombectomy* 10% 16% Thrombolytics 21% (6%) Core Peripheral 3% 6% Venous Insufficiency 7% 2% Vascular Access Q4 FY2022 FY2022 Midlines (10%) (18%) C3 (10%) 12% PICCs 8% (3%) Ports 16% 10% Dialysis 16
Slide 8: Fourth Quarter and Full-Year 2022 Results (unaudited)
Fourth Quarter and Full-Year 2022 Results (unaudited) $ in thousands (except per share data) Q4 FY2022 Q4 FY2021 Change FY2022 FY2021 Change Revenue $86,998 $76,842 13.2% $316,219 $291,010 8.7% Med Tech Med Device $22,611 $64,387 $16,150 $60,692 40.0% 6.1% $78,717 $237,502 $55,731 $235,279 41.2% 0.9
Slide 9: Fourth Quarter and Full-Year 2022 Gross Margin Walk
9 Fourth Quarter and Full-Year 2022 Gross Margin Walk Full-Year Fourth Quarter * Start-up costs include installation costs related to the Auryon lasers and costs related to transitioning the manufacturing of AlphaVac to AngioDynamics.
Slide 10: Full-Year 2022 Cash Walk
Full-Year 2022 Cash Walk i>) angiodynamics
Slide 11: Focused Transformation: U.S. Total Addressable Markets
11 FOCUSED TRANSFORMATION U.S. Total Addressable Markets FY2021 Launch of the Auryon System gives us access to the peripheral atherectomy market Planned Thrombectomy & NanoKnife System portfolio additions & new indications increase market access $3.0B 2-5% Mkt CAGR $6.0B 3-7% Mkt CAGR $8.0B 3-7% Mkt
Slide 12: Med Tech Platform – Expansion Opportunities
12 Med Tech Platform – Expansion Opportunities Developing our Med Tech platforms potentially expands our TAMs FY2023 TAM $6B Portfolio Expansion Pulmonary Embolism* Left Atrium Coronary Atherectomy** Arterial Thrombectomy European MedTech Platform Expansion** DVT Atherectomy Right Atrium Prostate* M
Slide 13: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation 13
Slide 14: Reconciliation of GAAP to Non-GAAP Net Income (Loss) and EPS
Reconciliation of GAAP to Non-GAAP Net Income (Loss) and EPS Reconciliation of Net Loss to Adjusted EBITDA Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items. Fiscal year 2021